Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

TOPEKA, Kan. (WIBW) - A little device is giving some people at risk for a stroke big peace of mind. It’s called the Watchman. It’s become a more frequent option for people with a heart condition ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...

CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the ...

POCATELLO, Idaho (KIFI) – Portneuf Heart and Vascular Institute, a leading innovator in cardiovascular healthcare, is proud to announce the successful implementation of its 200th Watchman Device. This ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

On the first day of the 2016 CardioStim sessions, I am happy to report a "positive" study on percutaneous left atrial appendage closure [1]. Notice I did not write Watchman. In Europe, the majority of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...